SLC Business Summary

Savior Lifetec Corporation (SLC) is a vertically integrated specialty pharmaceutical company specializing in the development and large-scale manufacturing of sterile carbapenem antibiotics, including Meropenem, Ertapenem, and Imipenem. The company generates revenue through three primary segments: the sale of high-purity Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs), high-margin Contract Development and Manufacturing Organization (CDMO) services for global pharmaceutical partners, and a growing health and wellness division under the SLC brand. SLC distinguishes itself through its advanced sterile crystallization and aseptic dry powder handling capabilities, maintaining US FDA and EU GMP-compliant facilities. In the global carbapenem market, SLC competes directly with major players such as Pfizer Inc., Merck & Co., Sun Pharmaceutical Industries, and Gland Pharma, positioning itself as a critical mid-stream and downstream supplier with a dominant market share in the niche sterile injectable space. Leadership is spearheaded by Chairwoman Rebecca Lee, an accounting and finance veteran with a Master’s from the University of Houston and extensive experience across multiple corporate boards, including Key Ware Electronics. The executive team is led by General Manager Chih-Fang Chen, a chemical engineering expert formerly of ScinoPharm Taiwan, who oversees the company’s technical operations and global manufacturing strategy. Supporting the core leadership are key executives such as Jonathan Chow, Director of Corporate Strategy, and Chen Yong-Fa, who serves as Executive Director and Chief Consultant. The company maintains a robust institutional investor base, with notable holdings from global financial entities including The Vanguard Group, State Street Global Advisors, and American Century Investment Management, reflecting its established position within the international biopharmaceutical supply chain.